A Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer

Diseases and Conditions Researched

Pancreas

What is the purpose of this trial?

This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary cancer or that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving trametinib is more effective than combination chemotherapy in treating patients with biliary cancer.


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Southwest Oncology Group (SWOG)
Dates:
Last Updated:
Study HIC#: 1402013371